Arybzhanov DT1*, Gantsev SHKH2 and Rysbekov MM2
1Federal State Budgetary Educational Institution of Further Professional Education “Bashkir State Medical University”, Ufa, Bashkortostan, Russia
2“South -Kazakhstan Medical Academy” JSC, Shymkent City Cancer Center, Shymkent, Kazakhstan
*Corresponding Author: Arybzhanov DT, Federal State Budgetary Educational Institution of Further Professional Education “Bashkir State Medical University”, Ufa, Bashkortostan, Russia.
Received: November 01, 2021; Published: May 20, 2022
The treatment of gastric cancer remains an urgent problem in Oncology. One of the unresolved problems in the treatment of gastric cancer remains the patients with liver metastases. With the development of interventional radiology, it became possible to treat gastric cancer patients with liver metastases.
The objective of the Research: Improving the treatment outcomes of gastric cancer patients with liver metastases by using transarterial chemoembolization (TACE).
Materials and Methods: We analyzed the results of 60 patients for the period 2008-2020, who sought medical attention due to metastatic liver disease, previously they received the combination therapy at various times. The average age of patients was 58.1 ± 5.8 years. When planning TACE, the general condition of all patients was over 80% according to Karnofsky Performance Status, according to ECOG 1-2. All patients underwent TACE of metastatic foci of the liver with the use of Lipiodol (6-8 ml) + Doxorubicinum (25 mg/m2). The interval between TACE cycles was 1.5-2 months. Each patient underwent 5-6 courses of TACE.
The Outcomes and its Discussion: Immediate results showed the treatment efficacy after 2 courses of TACE in 49 (81.7%) patients: partial regression - 36 (60%) patients, significant regression - 13 (21.6%) patients, stabilization of the process - 11 (18.3%) patients. The case follow -up showed the following results: 37 (61.7%) patients lived for 6 months, 24 (40%) patients lived for 12 months, 11 (18.3%) patients lived for 18 months, 8 (13.3%) patients lived for 24 months, and only 3 (5.0%) patients lived for 36 months. Median survival was 15.5 ± 1.2 months.
Conclusions: The immediate and long-term results of the research, performing TACE in gastric cancer patients with metastases was effective in 50% of cases. The case follow -up for 3 years showed that 37 (61.7%) patients lived for 6 months, 24 (40%) patients lived for 12 months, 11 (18.3%) patients lived for 18 months, 8 (13.3%) patients lived for 24 months, and only 3 (5.0%) patients lived for 36 months. At the same time, the median survival was 15.5 ± 1.2 months.
Currently, to improve the survival and quality of life of gastric cancer patients with metastases, the technique of transarterial chemoembolization can be considered as an effective, low-toxic method of treatment and it can be the method of choice.
Keywords: Chemoembolization; Gastric Cancer; Liver Metastases
Citation: Arybzhanov DT., et al. “Transarterial Chemoembolization in the Treatment of Gastric Cancer with Liver Metastases". Acta Scientific Gastrointestinal Disorders 5.6 (2022): 51-54.
Copyright: © 2022 Arybzhanov DT., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.